ATE361101T1 - Nahrungszusammensetzung die unverdauliche oligosaccharide enthält - Google Patents

Nahrungszusammensetzung die unverdauliche oligosaccharide enthält

Info

Publication number
ATE361101T1
ATE361101T1 AT04077394T AT04077394T ATE361101T1 AT E361101 T1 ATE361101 T1 AT E361101T1 AT 04077394 T AT04077394 T AT 04077394T AT 04077394 T AT04077394 T AT 04077394T AT E361101 T1 ATE361101 T1 AT E361101T1
Authority
AT
Austria
Prior art keywords
composition containing
food composition
containing indigestible
indigestible oligosaccharides
composition
Prior art date
Application number
AT04077394T
Other languages
English (en)
Inventor
Guenther Boehm
Rabet Laura M
Bernd Stahl
Johan Garssen
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE361101(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia Nv filed Critical Nutricia Nv
Application granted granted Critical
Publication of ATE361101T1 publication Critical patent/ATE361101T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/519—Breve

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pediatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04077394T 2004-08-24 2004-08-24 Nahrungszusammensetzung die unverdauliche oligosaccharide enthält ATE361101T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04077394.7A EP1629850B2 (de) 2004-08-24 2004-08-24 Nahrungszusammensetzung die unverdauliche Transgalaktooligosaccharide sowie verdauliche Galaktose-Saccharide enthält

Publications (1)

Publication Number Publication Date
ATE361101T1 true ATE361101T1 (de) 2007-05-15

Family

ID=34928473

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04077394T ATE361101T1 (de) 2004-08-24 2004-08-24 Nahrungszusammensetzung die unverdauliche oligosaccharide enthält

Country Status (19)

Country Link
US (4) US9566291B2 (de)
EP (5) EP1629850B2 (de)
JP (1) JP5142717B2 (de)
CN (2) CN101094687B (de)
AT (1) ATE361101T1 (de)
AU (2) AU2005275577B2 (de)
BR (1) BRPI0514536A (de)
CA (2) CA2576562C (de)
DE (1) DE602004006258T3 (de)
DK (2) DK1629850T4 (de)
ES (3) ES2286558T5 (de)
NZ (1) NZ553390A (de)
PL (2) PL1629850T5 (de)
PT (2) PT1629850E (de)
RU (2) RU2385725C2 (de)
SG (1) SG170119A1 (de)
TR (1) TR201820868T4 (de)
UA (1) UA89791C2 (de)
WO (2) WO2006022543A1 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
ATE361101T1 (de) 2004-08-24 2007-05-15 Nutricia Nv Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
US20060229366A1 (en) * 2005-04-07 2006-10-12 Lifschitz Carlos H Method for preventing or treating respiratory infections in infants
EP1714660A1 (de) * 2005-04-21 2006-10-25 N.V. Nutricia Uronsäure und Probiotika
EP1776877A1 (de) * 2005-10-21 2007-04-25 N.V. Nutricia Methode zur Förderung der Darmflora
US20070202215A1 (en) * 2006-02-28 2007-08-30 Zahramehran Salari Lak Dietary nutritional supplements for persons consuming alcohol products
PL1993576T3 (pl) 2006-03-07 2016-04-29 Nestec Sa Mieszanina synbiotyczna
WO2008054193A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
NL1032840C2 (nl) * 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
WO2008153377A1 (en) 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
CA2743334A1 (en) * 2007-11-12 2009-05-22 Samsara Medicin Ab Methods relating to breathing disorders
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
CN102006788A (zh) 2008-03-14 2011-04-06 雀巢产品技术援助有限公司 合益素混合物
EP2130440A1 (de) * 2008-06-06 2009-12-09 N.V. Nutricia Hemmen des E. Sakazakii-Wachstums
WO2009157759A1 (en) * 2008-06-23 2009-12-30 N.V. Nutricia Nutritional composition for improving the mammalian immune system
WO2010002241A1 (en) * 2008-06-30 2010-01-07 N.V. Nutricia Nutritional composition for infants delivered via caesarean section
US20100043075A1 (en) * 2008-08-13 2010-02-18 Autodesk, Inc. Licensing management utility
WO2010068086A1 (en) * 2008-12-11 2010-06-17 N.V. Nutricia Nutritional compositions with large lipid globule size
CA2752800C (en) 2009-02-24 2017-12-05 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US8784798B2 (en) * 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
BR112012000859B1 (pt) 2009-07-15 2021-08-03 N.V. Nutricia Uso de 2'-fucosilactose na fabricação de uma composição enteral
ES2989649T3 (es) 2009-07-15 2024-11-27 Nutricia Nv Mezcla de oligosacáridos no digeribles para estimular el sistema inmunitario
EP2322169A1 (de) * 2009-11-13 2011-05-18 Laboratorios Casen-Fleet, S.L. Zusammensetzung enthaltend ein DHA-Öl für den Einsatz in der Behandlung zystischer Fibrose
NL2004099C2 (en) * 2010-01-15 2011-07-18 Friesland Brands Bv Milk derived antigen specific antibodies for inducing an adaptive immune response, methods of preparation and uses thereof.
BE1019290A5 (nl) 2010-04-14 2012-05-08 Nutrition Sciences Nv Sa Voedingsupplement omvattende oligosachariden en middellange keten vetzuren.
EP2563372A4 (de) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc Präbiotische formulierungen und verwendungsverfahren dafür
EP2465509A1 (de) 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharid Zusammensetzung zur Behandlung von akuten Atemwegsinfektionen
EP2643017B1 (de) 2010-11-23 2019-05-22 Pantheryx, Inc. Behandlungszusammensetzungen und -verfahren mit undifferenzierten oder gemischten klinischen anwendungen aus einem breiten spektrum
WO2012087113A1 (en) 2010-12-24 2012-06-28 N.V. Nutricia Improved nutritional tablet
MY192208A (en) 2010-12-31 2022-08-08 Abbott Lab Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
EP3510873A1 (de) 2010-12-31 2019-07-17 Abbott Laboratories Nährstoffzusammensetzungen mit oligosacchariden aus menschlicher milch und nukleotiden sowie verwendungen davon zur behandlung und/oder prävention von enteralen virusinfektionen
SG10201606878QA (en) * 2010-12-31 2016-09-29 Abbott Lab Human milk oligosaccharides for modulating inflammation
NZ613180A (en) * 2010-12-31 2015-02-27 Abbott Lab Methods of using human milk oligosaccharides for improving airway respiratory health
JP5900792B2 (ja) * 2011-02-21 2016-04-06 国立大学法人信州大学 フェルラ酸結合型糖質の製造方法
US8563611B2 (en) * 2011-03-17 2013-10-22 Women's & Children's Health Research Institute Methods and compositions for promoting the respiratory development of an infant
RU2464796C1 (ru) * 2011-06-01 2012-10-27 Государственное образовательное учреждение высшего профессионального образования Воронежская государственная технологическая академия (ГОУ ВПО ВГТА) Способ получения фукозосодержащей функциональной добавки из молочной сыворотки
PT3366143T (pt) 2011-06-20 2025-01-07 Heinz Co Brands H J Llc Composições e métodos probióticos
WO2012177118A1 (en) * 2011-06-22 2012-12-27 N.V. Nutricia Method for reducing the occurrence of infection in young children
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
NL2007268C2 (en) 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
RU2471496C1 (ru) * 2011-11-17 2013-01-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии Сибирского отделения РАМН Средства, повышающие противоопухолевую и антиметастатическую активность цитостатических препаратов
CN104822279B (zh) 2012-12-18 2020-09-11 雅培制药有限公司 缓减应激症状的人乳寡糖
ITMI20122270A1 (it) * 2012-12-31 2014-07-01 Giovanni Mogna Terapia di supporto ai trattamenti di chemioterapia per i tumori, per la sindrome da immunodeficienza acquisita e per le leucemie.
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3470074B1 (de) 2013-05-10 2020-10-14 H.J. Heinz Company Brands LLC Probiotika
SE537951C2 (sv) * 2013-07-01 2015-12-01 Hero Ag Profylaktisk användning av modersmjölksersättning mot otit
US10357506B2 (en) 2013-11-15 2019-07-23 Nestec S.A. Compositions for use in the prevention or treatment of URT infections in infants or young children at risk
JPWO2016042831A1 (ja) * 2014-09-18 2017-04-27 協和化学工業株式会社 大腸の検査または手術のための処置用製剤
CN113862175A (zh) 2014-12-23 2021-12-31 4D制药研究有限公司 免疫调控
PL3193901T3 (pl) 2014-12-23 2018-10-31 4D Pharma Research Limited Polipeptyd pyrynowy i immunomodulacja
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MD3206700T2 (ro) 2015-06-15 2019-12-31 4D Pharma Res Ltd Compoziții conținând tulpini bacteriene
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180267A1 (es) 2015-06-15 2018-02-06 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
US20190000873A1 (en) * 2015-08-04 2019-01-03 Südzucker AG Prophylactic use of inulin against sinusitis
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2017085520A1 (en) 2015-11-20 2017-05-26 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MY186217A (en) 2015-12-15 2021-06-30 Nestle Sa Mixture of hmos
EP3397075A1 (de) * 2015-12-29 2018-11-07 N.V. Nutricia Nährstoffformel mit unverdaulichen oligosacchariden und nichtreplizierenden milchsäureproduzierenden bakterien
EP3207933A1 (de) * 2016-02-17 2017-08-23 Proponent Biotech GmbH Verwendungen von polyfructanen
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
JP6441536B2 (ja) 2016-03-04 2018-12-19 フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ Ｐｌｃ 細菌株を含む組成物
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
HUE054164T2 (hu) 2017-05-22 2021-08-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
MA49010B1 (fr) 2017-06-14 2020-11-30 4D Pharma Res Ltd Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations
LT3600363T (lt) 2017-06-14 2021-02-10 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
WO2019031961A1 (en) 2017-08-11 2019-02-14 N.V. Nutricia OLIGOSACCHARIDE OF HUMAN MILK TO IMPROVE PHYSICAL IMMUNE CONDITION
EP3479699A1 (de) * 2017-11-03 2019-05-08 Agriculture and Food Development Authority (TEAGASC) Zusammensetzung and verwendung davon
WO2019246316A1 (en) * 2018-06-19 2019-12-26 Evolve Biosystems, Inc. Novel oligosaccharides for use in prebiotic applications
CN108888762A (zh) * 2018-08-15 2018-11-27 福建傲农生物科技集团股份有限公司 一种含益生菌代谢产物的组合物
US12263192B2 (en) 2019-02-26 2025-04-01 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
EP4003061B1 (de) * 2019-07-23 2024-04-24 FrieslandCampina Nederland B.V. Ernährungszusammensetzung mit milchfett und immunglobulin
WO2021207180A1 (en) * 2020-04-06 2021-10-14 Abbott Laboratories Nutritional formulations for modulating respiratory-induced cytokines
US20230165881A1 (en) * 2020-04-30 2023-06-01 Kaleido Biosciences, Inc. Oligosaccharide compositions and methods of use thereof for treating viral infections
AU2021273198A1 (en) * 2020-05-13 2023-02-02 Glycosyn LLC Fucosylated oligosaccharides for prevention of coronavirus infection
AU2021271697A1 (en) 2020-05-13 2023-02-02 Glycosyn LLC 2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation
US20240366654A1 (en) * 2021-07-16 2024-11-07 Purdue Research Foundation Prebiotic composition and method of use to improve gastrointestinal health in patients with dysbiosis and leaky gut
CN117481270A (zh) * 2023-10-12 2024-02-02 希德罗(合肥)宠物用品有限公司 一种宠物用补血片剂及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH627079A5 (en) 1977-04-15 1981-12-31 Nestle Sa Process for preparing a protein concentrate containing immunological factors of milk origin
SE8301609D0 (sv) 1983-03-23 1983-03-23 Svenska Sockerfabriks Ab Forening och komposition for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutisk behandling
US4661345A (en) 1985-02-26 1987-04-28 The Rockefeller University Method for treating pertussis
NZ222902A (en) 1986-12-15 1990-08-28 Yakult Honsha Kk Method for producing galactooligosaccharide
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
SE462134B (sv) * 1987-10-22 1990-05-14 Biocarb Ab Livsmedel innehaallande lacto-n-tetraos och foerfarande foer dess framstaellning
DK0553113T3 (da) 1990-08-02 1999-08-09 Antex Biolog Inc Adhæsionsreceptorer for patogene eller opportunistiske mikroorganismer
US5902617A (en) 1992-05-19 1999-05-11 Pabst; Patrea L. Enzyme supplemented baby formula
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US5922344A (en) 1995-02-10 1999-07-13 Abbott Laboratories Product for prevention of respiratory virus infection and method of use
US5736533A (en) 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
EP1254664A3 (de) 1995-07-10 2004-01-02 Abbott Laboratories Verwendung von unverdaulichen Oligosacchariden zur Vorbeugung und Behandlung von Mittelohrentzündung bei Menschen
EP0756828B2 (de) 1995-08-04 2010-09-22 N.V. Nutricia Diätfasern enthaltende Nahrungszusammensetzung
CN1174998C (zh) * 1996-03-01 2004-11-10 诺瓦提斯公司 用于预防和治疗过敏的肽免疫原
WO1998044917A1 (en) 1997-03-27 1998-10-15 Bristol-Myers Squibb Company Use of docosahexanoic acid and arachidonic acid enhancing the growth of preterm infants
US6045854A (en) 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
US5906982A (en) 1997-03-31 1999-05-25 Abbott Laboratories Nutritional formulations containing Lacto-N-neoTetraose
US6145670A (en) * 1997-09-22 2000-11-14 Risser; William Bathtub spout with removable filter
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
ATE228779T1 (de) 1999-01-20 2002-12-15 Nutricia Nv Säuglingsnährpräparat
RU2141842C1 (ru) * 1999-05-05 1999-11-27 Бухтиярова Марина Георгиевна Способ пренатальной профилактики респираторного дистресс-синдрома у недоношенных новорожденных
RU2149633C1 (ru) * 1999-09-01 2000-05-27 Хачатрян Ашот Папикович Способ лечения иммунодефицитных состояний организма
EP1062873A1 (de) 1999-12-13 2000-12-27 N.V. Nutricia Verbessertes Säuglingsnährpräparat, Eiweisshydrolysat zur Verwendung in solchem Säuglingsnährpräparat, und Verfahren zur Herstellung solches Hydrolysates
DE10006989A1 (de) 2000-02-16 2001-08-23 Nutricia Nv Antiadhäsive Kohlenhydratmischung
FR2809312B1 (fr) * 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
JP5684964B2 (ja) * 2000-06-07 2015-03-18 ワトソン ファーマシューティカルズ， インコーポレイテッド （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
AU2001273614A1 (en) 2000-06-21 2002-01-02 James Zhou LIU Health promoting foods
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
DE10057976B4 (de) 2000-11-22 2005-02-03 Südzucker AG Mannheim/Ochsenfurt Verfahren zur Herstellung von Pektinhydrolyseprodukten
CA2432884C (en) 2000-12-27 2008-01-22 N.V. Nutricia Nutritional composition with health promoting action containing oligosaccharides
FI109602B (fi) 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
DE10147100A1 (de) * 2001-09-25 2003-04-17 Numico Res B V Antiinfektive Kohlenhydrate
WO2003026567A2 (en) * 2001-09-27 2003-04-03 St. Jude Children's Research Hospital, Inc. Use of neuraminidase inhibitors to prevent flu associated bacterial infections
DE60301677T2 (de) 2002-02-04 2006-07-06 Kyowa Hakko Kogyo Co., Ltd. Pharmazeutische und Lebenmittelzusammensetzungen mit einem Di- oder Oligosaccharid, das die Insulinfreisetzung steigert
EP2272522B1 (de) 2002-06-28 2017-09-06 Nestec S.A. Therapeutische Zusammensetzungen zur Verwendung bei der Prophylaxe oder Behandlung von Diarrhö
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1634599A1 (de) 2004-08-20 2006-03-15 N.V. Nutricia Immunstimulierende Kindernahrung
ATE361101T1 (de) 2004-08-24 2007-05-15 Nutricia Nv Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
NZ613180A (en) 2010-12-31 2015-02-27 Abbott Lab Methods of using human milk oligosaccharides for improving airway respiratory health

Also Published As

Publication number Publication date
AU2005275576B2 (en) 2011-07-07
DE602004006258T3 (de) 2013-08-29
EP1784222A1 (de) 2007-05-16
SG170119A1 (en) 2011-04-29
CA2576562A1 (en) 2006-03-02
WO2006022543A1 (en) 2006-03-02
TR201820868T4 (tr) 2019-01-21
ES2286558T3 (es) 2007-12-01
DE602004006258T2 (de) 2008-01-10
ES2704599T3 (es) 2019-03-19
CN101043904B (zh) 2012-04-18
ES2929515T3 (es) 2022-11-29
RU2007110813A (ru) 2008-10-10
AU2005275576A1 (en) 2006-03-02
DK1629850T3 (da) 2007-09-10
WO2006022542A1 (en) 2006-03-02
BRPI0514536A (pt) 2008-06-17
US20070274983A1 (en) 2007-11-29
ES2286558T5 (es) 2013-10-15
RU2007110822A (ru) 2008-10-10
EP1629850B1 (de) 2007-05-02
US8277835B2 (en) 2012-10-02
CN101094687A (zh) 2007-12-26
JP2008510803A (ja) 2008-04-10
DK2359858T3 (da) 2022-10-31
CA2576562C (en) 2016-03-01
US9566291B2 (en) 2017-02-14
UA89791C2 (ru) 2010-03-10
EP2851090A1 (de) 2015-03-25
AU2005275577A1 (en) 2006-03-02
DK1629850T4 (da) 2013-07-01
CN101043904A (zh) 2007-09-26
EP1784222B1 (de) 2018-10-10
CN101094687B (zh) 2011-07-27
EP2359858A1 (de) 2011-08-24
PT1629850E (pt) 2007-08-14
AU2005275576A2 (en) 2006-03-02
JP5142717B2 (ja) 2013-02-13
EP1784218A1 (de) 2007-05-16
PL2359858T3 (pl) 2022-12-19
RU2385714C2 (ru) 2010-04-10
CA2577926C (en) 2016-08-16
US20130102560A1 (en) 2013-04-25
EP1629850A1 (de) 2006-03-01
NZ553390A (en) 2009-11-27
RU2385725C2 (ru) 2010-04-10
DE602004006258D1 (de) 2007-06-14
EP1629850B2 (de) 2013-05-22
US20140296179A1 (en) 2014-10-02
PL1629850T5 (pl) 2013-09-30
AU2005275577B2 (en) 2011-03-10
US20080124323A1 (en) 2008-05-29
CA2577926A1 (en) 2006-03-02
EP2359858B1 (de) 2022-08-10
PL1629850T3 (pl) 2007-09-28
PT2359858T (pt) 2022-11-09

Similar Documents

Publication Publication Date Title
ATE361101T1 (de) Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
DK1721612T3 (da) Immunmodulerende oligosaccharider
WO2008076915A3 (en) Treatment of pigs with pcv2 antigen
IL158088A0 (en) Remedies for inflammatory bowel diseases
WO2008073464A3 (en) Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
WO2008043424A3 (en) Composition to treat or prevent gastrointestinal infection
UA93201C2 (ru) АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1
WO2003043583A3 (en) Treatment of immunological disorders using anti-cd30 antibodies
WO2004034930A3 (de) Implantat in der harnblase
EP1670490A4 (de) Verfahren zur hemmung von bakterienkolonisation
WO2005056601A3 (en) Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
SE0103695D0 (sv) A novel non-antibiotic strategy against OGIP infections based on a cereal product
ITMI20021881A1 (it) Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
ATE420852T1 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen
WO2001058483A3 (en) METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES
WO2006036213A3 (en) The use of gammaglobulin for the treatment of periodontal disease
EP1153604A4 (de) Inhibitoren der adp-ribosylierung und heilmittel für enterische bakterielle endotoxische infektionen die proanthocyanidin als wirkstoff enthalten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1629850

Country of ref document: EP